MODULITH SLC
STORZ MEDICAL AG – News

Fight against Alzheimer's dementia: STORZ MEDICAL celebrates the 100th NEUROLITH

Fight against Alzheimer's dementia: STORZ MEDICAL celebrates the 100th NEUROLITH

Transcranial Pulse Stimulation (TPS®) continues to be on the road to success: The 100th NEUROLITH® system was installed at the beginning of June 2022. The latest TPS® location is the Lengg Clinic in Zurich, Switzerland. Dr. med. Bartosz Bujan (Medical Director Neurorehabilitation) is one of the pioneers of TPS® in Switzerland and now offers the therapy option for patients with Alzheimer's dementia. To celebrate this important milestone and look to the future, a small celebration was held on June 16 at STORZ MEDICAL's headquarters.

»This is the beginning of a new, extremely exciting chapter in STORZ MEDICAL's corporate history,« said Manfred Schulz (Director Business Development & Neurology). »Just three years after its market launch, Transcranial Pulse Stimulation with the NEUROLITH® is offered in 100 clinics and 23 countries. More than 2,500 treatments - or 15,000 therapy sessions - have already been performed, and many more practices and clinics specializing in neurorehabilitation plan to add TPS® to their therapy spectrum in the near future. With TPS®, we want to contribute to maintaining the independence and quality of life of people with Alzheimer's dementia for as long as possible and to relieve the burden of family caregivers. In addition, our clinical research will investigate the effect of TPS® on other neurological conditions such as Parkinson's disease, stroke and depression.«

Anniversary of 100th NEUROLITH

The number of Alzheimer's patients is rising worldwide
In many countries, diseases such as Alzheimer's dementia are one of the greatest challenges for society and healthcare. According to the non-profit organization Alzheimer Switzerland, there are currently about 146,000 people living with Alzheimer's disease or another dementia in Switzerland alone. There are more than 30,000 new cases every year, and 95 percent of those affected are older than 65. By 2050, the number of people with the disease is expected to rise to more than 300,000.

Due to this rapid development, interest in new therapeutic approaches such as Transcranial Pulse Stimulation (TPS®) is growing worldwide. Especially in the early stages of the disease, a well-coordinated combination of therapeutic measures can make a decisive contribution to better patient care.

Anniversary of 100th NEUROLITH

2

Related Posts

 

Comments

No comments made yet. Be the first to submit a comment
Guest
Tuesday, 09 August 2022
Linkedin Channel Facebook Channel Instagram Channel Twitter Youtube Channel